[Form 4] ARTELO BIOSCIENCES, INC. Insider Trading Activity

Rhea-AI Filing Summary

Artelo Biosciences (ARTL) reported a director’s Form 4 detailing convertible note actions on 10/28/2025. A portion of a May 1, 2025 convertible note automatically converted into a warrant with a $6.24 exercise price. The remaining portion was converted and reinvested into a new October Note and a second warrant with a $3.40 exercise price.

The Form 4 lists two new warrants for 6,846 and 12,566 shares of common stock, each expiring on 10/28/2030. The October Note may be converted, at the holder’s election, into common stock at any time prior to repayment of principal and accrued interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FAVORITO TAMARA A

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Convertible Promissory Note	(1)(2)	10/28/2025		C(1)(2)			$25,000	05/01/2025	10/28/2025	Common Stock	(1)(2)	$25,000	$0.00	D
Warrant (right to buy)	$6.24	10/28/2025		C(1)(2)		6,846		10/28/2025	10/28/2030	Common Stock	6,846	(2)(1)	6,846	D
Warrant (right to buy)	$3.4	10/28/2025		C(1)(2)		12,566		10/28/2025	10/28/2030	Common Stock	12,566	(1)(2)	12,566	D
Convertible Promissory Note	$3.4	10/28/2025		C(1)(2)		$19,793		10/28/2025	04/28/2026	Common Stock	(1)(2)	$19,793	$19,793	D

Explanation of Responses:

1. Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

2. On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

Remarks:

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ARTL disclose in this Form 4?

A director reported converting portions of a prior note into a $6.24 warrant, and converting and reinvesting the remainder into an October Note and a $3.40 warrant.

How many shares are covered by the new ARTL warrants?

The filing lists warrants covering 6,846 and 12,566 shares of common stock.

What are the exercise prices and expirations of the ARTL warrants?

The warrants have exercise prices of $6.24 and $3.40, each expiring on 10/28/2030.

What is the ARTL October Note mentioned in the filing?

It is a new convertible note from 10/28/2025 that the holder may convert into common stock prior to full repayment of principal and accrued interest.

Who filed the ARTL Form 4 and what is their role?

A director of Artelo Biosciences filed the Form 4 as a single reporting person.

What is the transaction date for ARTL’s reported insider activity?

The earliest transaction date reported is 10/28/2025.